Lauryn S. Bracken

发表

Up-regulation of Survivin during Immortalization of Human Myofibroblasts Is Linked to Repression of Tumor Suppressor p16INK4a Protein and Confers Resistance to Oxidative Stress*

R. Lock, K. MacKenzie, C. Kan, 2013, The Journal of Biological Chemistry.

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

R. Dickins, C. Mullighan, R. Levine, 2013, Cell reports.

LYMPHOID NEOPLASIA AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

P. Houghton, W. Wilson, R. Lock, 2015 .

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

P. Houghton, W. Wilson, R. Lock, 2015, Blood.

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling

G. Berx, F. Speleman, J. Soulier, 2015, Nature Communications.

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

M. Loh, C. Mullighan, P. Houghton, 2014, Molecular Cancer Therapeutics.

Evaluation of the In Vitro and In Vivo Ef ﬁ cacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

M. Loh, C. Mullighan, P. Houghton, 2015 .

Evaluationof the InVitro and InVivo Ef fi cacyof the JAK Inhibitor AZD 1480 against JAK-Mutated Acute Lymphoblastic Leukemia

M. Loh, C. Mullighan, P. Houghton, 2015 .